Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

FAQs

Find answers to frequently asked questions about Syngene.

How is Syngene different from Biocon?

We are two different entities, and the nature of our work is different. We are a contract research development and manufacturing organization (CRDMO), whereas Biocon is a biopharmaceutical company.

Biocon primarily focuses on the development, manufacturing, and marketing of biopharmaceuticals, including biosimilars, novel biologics, and small-molecule drugs. On the other hand, Syngene International specializes in contract research and manufacturing services. We also provide integrated drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies.

Syngene International is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies.

Discovery: Our Discovery Services division is responsible for conducting early stage research, from identifying biological targets relevant to disease in patient populations to delivering drug candidates for further development. Our capabilities encompass chemistry, biology, safety assessment, and computational and data sciences for traditional small molecule therapeutics, biologics, and specialty modalities such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. Syngene SynVent™, part of Discovery Services, is our platform for integrated drug discovery offering clients a complete project delivery capability, utilizing our differentiated technologies and scientific expertise.

Development: With a focus on small molecules, our Development Services division takes drug candidates and provides a range of services, from pre-clinical to clinical trials, including drug substance, drug product development, and associated services in order to demonstrate the safety, tolerability, and efficacy of drugs. Our development capabilities include advancing highly potent active pharmaceutical ingredients and oligonucleotides with therapeutic and diagnostic applications, from laboratory to manufacturing scale. Our expertise also includes working with performance chemicals and specialty materials using synthetic organic chemistry and polymer chemistry. We integrate analytical services such as method development, validation, transfer, and reference standard qualification throughout the development process.

Manufacturing: Manufacturing Services offers commercial-scale manufacturing of small molecules from our cGMP-compliant API manufacturing campus in Mangalore and development and manufacturing services for large molecules from our biologics manufacturing facility in Bangalore which has been approved by the US and European regulatory authorities.

Dedicated R&D Centers: These are multi-disciplinary teams based in dedicated facilities focusing on biopharmaceutical research for clients including BMS, Amgen and Baxter. This model offers a turn-key solution to those clients that want to operate a dedicated research center, at scale, without having to make long-term capital investments and with the ability to fully integrate into their existing research network while maintaining the flexibility to scale up and down easily.

Yes, besides the US FDA approval, Syngene’s facilities are approved by various international regulators including European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), College of American Pathologists (CAP) and Russian Regulatory Authority.  We operate in a highly regulated industry that has controls, checks and balances apart from governance and rigor. We operate to a single standard of global science, driven by excellence and a high compliance regulatory mindset. Whether it’s the US FDA, European or Indian regulators, we meet their standards every day. It is one of the things that reassures our global clients. Syngene is also accredited with ISO 9001 (Quality Management), ISO 45001 (Occupational Health and Safety Management System), ISO 14001 (Environmental Management System), ISO/IEC 17025 (Competence of testing and calibration laboratories), ISO/IEC 27001 (Information Security), ISO 15189 (Quality and competence in medical laboratories) and ISO 13485 (Medical devices). 

We offer integrated services spanning the value chain from discovery to development and commercial scale manufacturing to more than 450 clients including 11 of the top 15 pharmaceutical companies in the world. The Company’s strategic partnerships and collaborations range from small biotechs to big pharma companies such as GSK, Janssen, Zoetis and Merck KGaA, including dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb.  We pride ourselves on our many deep, long-term client relationships.  We have a high client retention rate for over 10-20 years with large biopharma relationships. As a strategic partner to our clients, often working as an extension of their internal scientific teams, we continue to bring them innovative, flexible and efficient approaches to scale up rapidly.

Syngene recognizes the transformative potential of Artificial Intelligence (AI) and Machine Learning (ML) in revolutionizing the drug discovery and development space. By leveraging innovative advancements in AI, IoT, and big data analytics, Syngene has experienced a significant impact on various aspects of its business operations. Specifically, the integration of AI and data-driven methodologies has the potential to revolutionize the traditional drug discovery paradigm by introducing speed, minimizing late-stage failures, improving efficiencies, and cost-effectiveness. Syngene is at the forefront of these innovations, developing specialized AI tools such as Syn.AITM and SarchitectTM tailored for drug discovery. These tools enable rapid identification of promising drug targets and candidates, streamline the confirmation process, and optimize the design and properties of drug compounds.

Furthermore, AI is enhancing efficiency and quality at an enterprise level, with generative AI facilitating tasks such as drafting contracts, responding to RFPs, and writing reports with benchmarked quality. Additionally, machine learning capabilities are continuously improving institutional capabilities, such as drafting legal documents and planning procurement more accurately. Overall, Syngene views AI and ML as key drivers in making its operating model future-fit and customer-centric, leading the way towards digital transformation in the pharmaceutical industry.

We prioritize diversity, equity, and inclusion, striving to cultivate a workforce rich in varied perspectives, skills, and experiences to enhance innovation and decision-making. Our commitment extends to fostering gender-neutral career paths. Presently, 28% of our workforce comprises women, significantly surpassing the industry average of 11% in India. Moreover, we’re proud to note that 20% of senior management positions are held by women, marking a notable increase from 11% in 2022.

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details